Stockscreener 앱 받기
182.64
22.75%
33.85
Axsome Therapeutics Inc 주식(AXSM)의 최신 뉴스
Axsome (AXSM) Stock; Climbs Nearly 23% After FDA Accelerates Alzheimer’s Review - CoinCentral
Moody Aldrich Partners LLC Trims Stock Holdings in Axsome Therapeutics, Inc. $AXSM - MarketBeat
Axsome (AXSM) stock jumps after FDA sets April decision date for Alzheimer’s agitation filing - ts2.tech
Axsome stock jumps 23% after FDA sets April 30 deadline for Alzheimer’s agitation review - ts2.tech
Why Axsome Therapeutics Stock Rocketed Higher to End 2025 - The Globe and Mail
Axsome Therapeutics Stock Skyrockets: What’s Next? - StocksToTrade
Axsome stock jumps nearly 23% after FDA fast-tracks AXS-05 for Alzheimer’s agitation - ts2.tech
This Pharmaceutical Giant Fell by 10% After a Setback: Time to Sell the Stock? - AOL.com
Key Takeaways - StocksToTrade
Axsome’s Surprising Surge: What’s Next ? - timothysykes.com
From Haiti to Wall Street to Big Pharma: Herriot Tabuteau is on a $6B mission to heal the brain - AOL.com
Axsome Therapeutics price target raised to $217 from $202 at Mizuho - TipRanks
Baird reiterates Outperform rating on Axsome Therapeutics stock By Investing.com - Investing.com Nigeria
Axsome Therapeutics (AXSM) stock jumps 23% after FDA priority review for Alzheimer’s agitation filing - ts2.tech
Axsome Therapeutics says AXS-12 NDA submission on track for January - TipRanks
Baird reiterates Outperform rating on Axsome Therapeutics stock - Investing.com
Axsome Therapeutics Stock Surge Analysis - timothysykes.com
Axsome Therapeutics: Late-Stage CNS Pipeline and Regulatory Tailwinds Support Buy Rating - TipRanks
Mizuho raises Axsome Therapeutics stock price target on regulatory progress - Investing.com
Axsome stock jumps on FDA priority review for Alzheimer’s agitation drug - Investing.com
Mizuho raises Axsome Therapeutics stock price target on regulatory progress By Investing.com - Investing.com UK
Pharmaceutical Stocks To Follow NowDecember 31st - MarketBeat
Mizuho Lifts Price Target on Axsome Therapeutics to $217 From $202, Keeps Outperform Rating - marketscreener.com
Oppenheimer raises Axsome Therapeutics stock price target to $220 on FDA news - Investing.com
William Blair Maintains Axsome Therapeutics(AXSM.US) With Buy Rating - 富途牛牛
Axsome Therapeutics announces FDA acceptance, priority review of AXS-05 sNDA - TipRanks
Morgan Stanley reiterates Overweight rating on Axsome stock with $196 target - Investing.com
Axsome Therapeutics Stock Jumps After FDA Grants Priority Review For Alzheimer's Agitation Drug - Investor's Business Daily
Axsome’s Auvelity for Alzheimer’s agitation gets priority review - BioWorld MedTech
Axsome Advances Toward FDA Filing For Drug To Treat Narcolepsy - Stocktwits
Axsome Therapeutics Poised for Growth as AXS-05 Nears FDA Approval - timothysykes.com
Pharma Stock Soars to Record Highs on FDA Buzz - Schaeffer's Investment Research
Axsome nabs speedy review of Alzheimer's agitation drug hopeful - FirstWord Pharma
Why Is Axsome Therapeutics Stock Soaring Wednesday?Axsome Therapeutics (NASDAQ:AXSM) - Benzinga
Axsome Therapeutics (NASDAQ:AXSM) Hits New 52-Week High on Analyst Upgrade - MarketBeat
Axsome Therapeutics, Plug Power And Other Big Stocks Moving Higher On Wednesday - Benzinga
Biggest stock movers Wednesday: Vanda Pharmaceuticals, Axsome Therapeutics and Cybin - Seeking Alpha
Axsome Therapeutics stock hits all-time high at 160.6 USD By Investing.com - Investing.com Nigeria
Axsome Therapeutics stock hits all-time high at 160.6 USD - Investing.com
Axsome Therapeutics shares gain 8.3% after FDA grants priority review for co's Alzheimer's agitation drug - marketscreener.com
Axsome Therapeutics stock holds Buy rating at Truist on AXS-05 sNDA acceptance - Investing.com
Axsome Therapeutics (NASDAQ:AXSM) Has Debt But No Earnings; Should You Worry? - 富途牛牛
Axsome stock gets Buy rating from TD Cowen on FDA priority review - Investing.com
Needham & Company LLC Forecasts Strong Price Appreciation for Axsome Therapeutics (NASDAQ:AXSM) Stock - MarketBeat
Axsome stock surges after FDA grants priority review for Alzheimer’s drug - Investing.com
Why Axsome Therapeutics Shares Are Slipping Now - TipRanks
Axsome Therapeutics Says US FDA Accepts New-Drug Application Filing for Alzheimer's Disease Agitation Drug - marketscreener.com
Axsome Therapeutics to File AXS-12 New Drug Application in Narcolepsy After FDA Feedback - marketscreener.com
Axsome Advances AXS-12 Toward NDA Filing for Narcolepsy - TipRanks
Axsome wins FDA priority review for Auvelity in Alzheimer’s disease agitation - Seeking Alpha
Axsome Therapeutics shares gain 1.4% premarket after FDA grants priority review for co's Alzheimer's agitation drug - marketscreener.com
Axsome Therapeutics Announces FDA Acceptance and Priority Review of Supplemental New Drug Application for AXS-05 for the Treatment of Alzheimer’s Disease Agitation - The Manila Times
Axsome Therapeutics Announces FDA Pre-NDA Meeting Minutes for AXS-12 in Narcolepsy Supporting NDA Submission - The Manila Times
FDA Accepts Axsome's SNDA For AXS-05 In Alzheimer's Agitation With Priority Review - Nasdaq
Axsome Therapeutics Announces FDA Priority Review and Pre-NDA Meeting Outcomes - TradingView — Track All Markets
FDA supports Axsome’s NDA submission for narcolepsy drug AXS-12 By Investing.com - Investing.com Australia
FDA grants priority review for Axsome’s Alzheimer’s agitation drug - Investing.com
FDA supports Axsome’s NDA submission for narcolepsy drug AXS-12 - Investing.com India
FDA grants priority review for Axsome’s Alzheimer’s agitation drug By Investing.com - Investing.com UK
Axsome Therapeutics Advances Toward NDA Submission For AXS-12 In Narcolepsy - Nasdaq
Axsome Therapeutics on Track to Submit NDA for AXS-12 in Narcolepsy by January 2026 - Quiver Quantitative
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Sees Significant Drop in Short Interest - MarketBeat
Behavioral Patterns of AXSM and Institutional Flows - Stock Traders Daily
Why Axsome Therapeutics Inc. stock is rated strong buyMarket Sentiment Indicators & You’ll Thank Yourself in 6 Months - bollywoodhelpline.com
0.90%
자본화:
|
볼륨(24시간):